Spending on health care in the US alone reached USD 4.5 trillion in 2023, an amount greater than the GDP of Japan. Priorities within the sector have changed since the Covid pandemic, though it remains the ultimate long-term theme as the global population gets older and sicker.
“Globally, several structural factors are driving this trend, including an aging population, with projections indicating that by 2050, one in every six individuals worldwide will be over 65, compared with one in 11 currently,” says Cornuz, healthy living analyst with Robeco’s thematic equity team.
“Then there is the rising burden of chronic conditions, such as cardiovascular diseases, cancer or diabetes, and increased demand for health care services in emerging markets. This provides an opportunity for investors to discover companies that can apply new AI technologies, develop new cures, and improve the effectiveness of health care spending generally.”
“However, there remain some challenging headwinds, including reduced revenues for health care suppliers post-Covid, drug price controls, and regulatory uncertainty; rebates for Medicare in the US created a challenging backdrop for parts of the sector in 2023.”
“On top of that, the launch of GLP-1 drugs for obesity led to massive dispersion in performance between Big Pharma, MedTech and other health care sub-sectors. While more dispersion and macro uncertainty are likely in 2024, this provides the active stock picker with more opportunities than seen in recent years, with valuation support and more divergence between winners and losers.”
![2024-06-07-monthly-outlook.png](https://images.ctfassets.net/tl4x668xzide/3YsDhWoUQIgUedAt0ckuY9/81e8b1e6ee599de3a564ae4b172a3a80/2024-06-07-monthly-outlook.png?fit=pad&w=800&h=456&f=center&fm=webp)
The percentage of GDP spent on health care; the US leads the pack at 17.8%.
Source: Morgan Stanley
Three factors stand out
Cornuz says three factors stand out, led by recovery in the biotech and life sciences sectors, the prospect of no upsets in the upcoming US Presidential and Congressional elections, and a refocus on attractive therapeutic areas beyond GLP-1.
“M&A activity in biotech has seen a pick-up in the year to date that is likely to persist, albeit with a shift towards acquiring later-stage assets, as Big Pharma replenishes its pipelines,” she says.
“Health care is not expected to be a central theme in the US elections. Although large cap pharma and managed care remain exposed to headwinds such as repeal of the Affordable Care Act, other sub-sectors such as life sciences tools or contract research organizations (CROs) or contract manufacturing organizations (CMOs) involved in making new drugs should remain insulated.”
“Finally, the market focus is moving past drugs for obesity to other product cycles such as tackling Alzheimer’s disease or developing respiratory vaccines.”
Pipelines, patents and profits
Cornuz says the pipeline of new drugs underpins growth in the sector, particularly as patents expire for blockbuster products. Patents provide immunity from competition while they are active, making them into de facto monopolies, but other companies can manufacture the same product once they expire.
“The race to discover a Covid-19 vaccine put a spotlight on the industry’s ability to rapidly innovate, but the patent cliff is always a drag on Big Pharma that is set to cost the industry USD 180 billion in lost revenue by the end of the decade,” Cornuz says.
“So, building on the acceleration of innovation through faster product cycles or M&A is a key theme for the sector. Notable therapeutic areas offering growth opportunities include oncology, immunology, diabetes/obesity, and neurology, particularly for tackling Alzheimer's disease.”
AI lends a helping hand
Pipelines are a risky business, since developing a new drug typically takes eight to ten years and costs USD 1-2 billion per product, with only one out of every ten candidates ever reaching the market with regulatory approval. So, can artificial intelligence help?
“AI has the potential to shorten product development by contributing to faster drug discovery and the reduction of clinical trial failure rates,” Cornuz says. “With data integration, trend recognition and predictive modeling, AI can speed up the understanding of diseases and help to identify future winners in the traditional drug discovery process, while machine learning algorithms can optimize clinical trial designs.”
“Beyond drug development, data-driven digital health care tools have the potential to improve patient outcomes while reducing inefficiencies. In a sector plagued with shortages of skilled labour, AI can help facilitate patient care from pre-appointment to diagnostics, and reduce hospitals’ administrative burdens.”
Spending on digitalization
Digitalizing the sector – the subject of a past engagement theme at Robeco – is also both a long-term cost and opportunity for a sector that relies on accurate medical records and the ability to track the effectiveness of doctors’ prescriptions. Investments in digital health totalled USD 45 billion during the pandemic, ranging from clinical trials technology to home health and wellness.
“From 2020-2022, health care was the sector with the highest capital invested in AI after IT,” Cornuz says. “Funding since the pandemic ended has steeply declined, pressured by rising interest rates.”
“The headwinds facing the sector are well understood; what is not is how investments in digital and AI tools are providing clear productivity gains. That is yet to come, and will be an issue for investors to consider in this vibrant but always challenging sector.”
Read the full monthly outlook here時刻把握我們最新市場觀點及電子報
接收荷寶電子報,率先閱讀最新洞察分析,並構建最綠色的投資組合。
免責聲明
本文由荷宝海外投资基金管理(上海)有限公司(“荷宝上海”)编制, 本文内容仅供参考, 并不构成荷宝上海对任何人的购买或出售任何产品的建议、专业意见、要约、招揽或邀请。本文不应被视为对购买或出售任何投资产品的推荐或采用任何投资策略的建议。本文中的任何内容不得被视为有关法律、税务或投资方面的咨询, 也不表示任何投资或策略适合您的个人情况, 或以其他方式构成对您个人的推荐。 本文中所包含的信息和/或分析系根据荷宝上海所认为的可信渠道而获得的信息准备而成。荷宝上海不就其准确性、正确性、实用性或完整性作出任何陈述, 也不对因使用本文中的信息和/或分析而造成的损失承担任何责任。荷宝上海或其他任何关联机构及其董事、高级管理人员、员工均不对任何人因其依据本文所含信息而造成的任何直接或间接的损失或损害或任何其他后果承担责任或义务。 本文包含一些有关于未来业务、目标、管理纪律或其他方面的前瞻性陈述与预测, 这些陈述含有假设、风险和不确定性, 且是建立在截止到本文编写之日已有的信息之上。基于此, 我们不能保证这些前瞻性情况都会发生, 实际情况可能会与本文中的陈述具有一定的差别。我们不能保证本文中的统计信息在任何特定条件下都是准确、适当和完整的, 亦不能保证这些统计信息以及据以得出这些信息的假设能够反映荷宝上海可能遇到的市场条件或未来表现。本文中的信息是基于当前的市场情况, 这很有可能因随后的市场事件或其他原因而发生变化, 本文内容可能因此未反映最新情况,荷宝上海不负责更新本文, 或对本文中不准确或遗漏之信息进行纠正。